Kathryn Haviland
Directeur Général chez BLUEPRINT MEDICINES CORPORATION
Fortune : 5 M $ au 30/04/2024
Profil
Kathryn Haviland est membre du conseil d'administration de Fulcrum Therapeutics, Inc. et directrice de l'exploitation de Blueprint Medicines Corp, membre de la Harvard Business School Health Industry Alumni Association et membre du Biopharma Executive Council. Mme Haviland a précédemment occupé le poste de vice-présidente des maladies rares chez Idera Pharmaceuticals, Inc, de chef du développement commercial chez Sarepta Therapeutics, Inc et de directrice exécutive du développement commercial chez PTC Therapeutics, Inc. Elle a obtenu un diplôme de premier cycle de l'université de Wesleyan et un MBA de la Harvard Business School.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/03/2024 | 59 912 ( 0,10% ) | 5 M $ | 30/04/2024 | |
| 31/03/2024 | 0 ( -.--% ) | - $ | 30/04/2024 |
Postes actifs de Kathryn Haviland
| Sociétés | Poste | Début |
|---|---|---|
| BLUEPRINT MEDICINES CORPORATION | Directeur Général | 04/04/2022 |
| FULCRUM THERAPEUTICS, INC. | Président | 10/01/2022 |
| Harvard Business School Health Industry Alumni Association | Corporate Officer/Principal | - |
Biopharma Executive Council
 Biopharma Executive Council Miscellaneous Commercial ServicesCommercial Services Biopharma Executive Council is a membership council that operates at the executive level in the biotech and pharmaceutical industries. The private company is based in Boston. | Corporate Officer/Principal | - |
Bicara Therapeutics, Inc.
 Bicara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bicara Therapeutics, Inc. is a company that develops first-in-class bifunctional antibodies for the treatment of solid tumors. The company is based in Cambridge, MA. The company's lead product candidate, bca101, is a first-in-class egfr/tgf-?-trap bifunctional antibody in clinical development for multiple tumor types. The company's bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Bicara has a deep pipeline of promising bifunctional antibodies and other biologics for treating solid tumors. The CEO of the company is Claire Mazumdar. | Directeur/Membre du Conseil | 16/10/2023 |
Anciens postes connus de Kathryn Haviland
| Sociétés | Poste | Fin |
|---|---|---|
Idera Pharmaceuticals, Inc.
 Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Corporate Officer/Principal | 01/12/2015 |
| SAREPTA THERAPEUTICS, INC. | Corporate Officer/Principal | 01/04/2014 |
| PTC THERAPEUTICS, INC. | Corporate Officer/Principal | 01/06/2012 |
Formation de Kathryn Haviland
| Wesleyan University | Undergraduate Degree |
| Harvard Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| SAREPTA THERAPEUTICS, INC. | Health Technology |
| PTC THERAPEUTICS, INC. | Health Technology |
| BLUEPRINT MEDICINES CORPORATION | Health Technology |
| FULCRUM THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Health Technology |
| Harvard Business School Health Industry Alumni Association | |
Biopharma Executive Council
Biopharma Executive Council Miscellaneous Commercial ServicesCommercial Services Biopharma Executive Council is a membership council that operates at the executive level in the biotech and pharmaceutical industries. The private company is based in Boston. | Commercial Services |
Bicara Therapeutics, Inc.
Bicara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bicara Therapeutics, Inc. is a company that develops first-in-class bifunctional antibodies for the treatment of solid tumors. The company is based in Cambridge, MA. The company's lead product candidate, bca101, is a first-in-class egfr/tgf-?-trap bifunctional antibody in clinical development for multiple tumor types. The company's bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Bicara has a deep pipeline of promising bifunctional antibodies and other biologics for treating solid tumors. The CEO of the company is Claire Mazumdar. | Health Technology |
